OCTIMET Oncology

About:

OCTIMET has licensed from Janssen Pharmaceutica, highly selective MET kinase inhibitors with clean safety profiles

Top Investors: Omnes Capital, Agentschap Innoveren & Ondernemen, V-Bio Ventures, Fund+, Droia Ventures

Description:

OCTIMET oncology’s overall strategy is to advance the development of discovery stage molecules by employing innovative patient selection and pharmacodynamic biomarker-based strategies, as well as an innovative clinical development strategy.

Total Funding Amount:

12.4M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Beerse, Antwerpen, Belgium

Founded Date:

2016-01-01

Contact Email:

bd(AT)octimet.com

Founders:

Ann Meulemans, Paolo Comoglio, Philip Owen, Tim Perera

Number of Employees:

11-50

Last Funding Date:

2018-08-08

IPO Status:

Private

Industries: